Best of SWOG: Better Late Than Never
If you're attuned to the rhythm of SWOG's calendar, you may have noticed we did not host a Best of SWOG webinar at the very end of January, as we usually do. Never fear – we were simply giving ourselves some elbow room to complete and submit our NCTN grant application.
Application submitted (that was last week’s news), we will mount our next Best of SWOG webinar on Wednesday, March 26th, 2-3 pm ET / 11 am – 12 pm PT – a little late, but worth the wait. An invitation to register for the webinar should land in your inbox soon, or you can click here to register (if you cannot wait).
This month’s installment will be the eighth in the series (the first was in July 2020) and will bring to 35 the number of SWOG investigators, representing the full range of our research committees, who have presented work at a Best of SWOG webinar.
About one-half of those talks have been “Best of SWOG at ASCO” re-presentations of work that had been presented a few weeks earlier at the annual meeting of the American Society of Clinical Oncology.
But Best of SWOG has also included work that premiered at many of the other big meetings in our field – including ASH, ASTRO, ESMO, SABCS, and SITC, not to mention at other ASCO meetings as well.
Other Best of SWOG presentations have featured work that had been recently published in high-impact journals, ranging from the Journal of Clinical Oncology to Lancet Oncology.
Here is our list of presenters and topics for the winter 2025 edition.
- Kanwal P. Raghav, MD, MBBS – S1613 results: Dual HER2-inhibitor therapy vs EGFR inhibitor-based therapy for HER2-positive metastatic colorectal cancer (gastrointestinal cancers)
- Kendra L. Sweet, MD – S1712 results: Adding ruxolitinib to tyrosine kinase-inhibitor treatment for chronic-phase chronic myeloid leukemia (leukemia)
- Joseph M. Unger, PhD – Risk prediction model to identify patients with advanced cancer most likely to need acute care (cancer care delivery)
- Ian M. Thompson, Jr., MD – Analysis of long-term complications from prostate cancer treatment (genitourinary cancers)
- S1609 DART results from 2024: Six years on (early therapeutics and rare cancers)
The first results from a DART trial cohort were presented at the American Association for Cancer Research’s annual meeting in March of 2019. Six years on (and counting), the trial continues to change practice. So even though we’re still finalizing our DART presenter for the 26th (the competition must be fierce), you know the content will be high impact.
Each rapid-fire Best of SWOG talk will be followed by a few minutes for audience questions. We again will offer attendees one hour of Continuing Medical Education (CME) credit for the event, thanks to The Hope Foundation. We’ll also post the recording to SWOG’s YouTube channel and will make it available via our learning management system. Register now to attend.
And expect a return to SWOG’s usual rhythms with a next Best of SWOG a few weeks after this June’s ASCO annual meeting.
Speaking of registering, registration is now open for SWOG’s spring group meeting, April 30 – May 3, at the Hyatt Regency San Francisco. Reserve your place – and your room – early.
Other Recent Stories
